Literature DB >> 17239319

Male overactive bladder: the role of urodynamics and anticholinergics.

Scott MacDiarmid1, Alexandra Rogers.   

Abstract

Millions of men suffer from overactive bladder and lower urinary tract symptoms. The adverse effects on quality of life and costs associated with the condition have been well described. In men, the pathophysiology of lower urinary tract symptoms may be from a number of causes including bladder outlet obstruction, detrusor overactivity, or both. Increasing data and clinical experience support the efficacy and safety of anticholinergics in men; the rate of urinary retention has been equal to that of placebo in short-term studies. Urodynamics play a vital role in defining the bladder and/or outlet dysfunction and help direct one's therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17239319     DOI: 10.1007/s11934-007-0023-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  28 in total

1.  Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function.

Authors:  P Abrams
Journal:  BJU Int       Date:  1999-07       Impact factor: 5.588

Review 2.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

3.  Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract.

Authors:  Gabriella Engström; Lars Henningsohn; Gunnar Steineck; Jerzy Leppert
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

Review 4.  The Abrams-Griffiths nomogram.

Authors:  C S Lim; P Abrams
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

5.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors:  P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

6.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.

Authors:  M J Hyman; A Groutz; J G Blaivas
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

7.  The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms.

Authors:  T J Peters; J L Donovan; H E Kay; P Abrams; J J de la Rosette; D Porru; J W Thüroff
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate.

Authors:  Ger E P M Van Venrooij; Harm H E Van Melick; Mardy D Eckhardt; Tom A Boon
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

9.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

View more
  2 in total

Review 1.  Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia?

Authors:  Kyu-Sung Lee; Hye Won Lee; Deok Hyun Han
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

2.  Urodynamic investigation by telemetry in Beagle dogs: validation and effects of oral administration of current urological drugs: a pilot study.

Authors:  Stéphanie Noël; Laurent Massart; Annick Hamaide
Journal:  BMC Vet Res       Date:  2013-10-08       Impact factor: 2.741

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.